JP2012501332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501332A5 JP2012501332A5 JP2011525134A JP2011525134A JP2012501332A5 JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5 JP 2011525134 A JP2011525134 A JP 2011525134A JP 2011525134 A JP2011525134 A JP 2011525134A JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- lyophilized
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9232608P | 2008-08-27 | 2008-08-27 | |
| US61/092,326 | 2008-08-27 | ||
| PCT/US2009/054842 WO2010027766A1 (en) | 2008-08-27 | 2009-08-25 | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Division JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501332A JP2012501332A (ja) | 2012-01-19 |
| JP2012501332A5 true JP2012501332A5 (enExample) | 2012-10-04 |
| JP5931442B2 JP5931442B2 (ja) | 2016-06-08 |
Family
ID=41495339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525134A Active JP5931442B2 (ja) | 2008-08-27 | 2009-08-25 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8263748B2 (enExample) |
| EP (1) | EP2331078B1 (enExample) |
| JP (2) | JP5931442B2 (enExample) |
| CN (1) | CN102202655B (enExample) |
| AU (1) | AU2009288419B2 (enExample) |
| CA (1) | CA2734919C (enExample) |
| MX (1) | MX2011002159A (enExample) |
| WO (1) | WO2010027766A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| KR102049223B1 (ko) | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항－ｉｌ－２３ 항체 |
| BR112014009866A2 (pt) | 2011-10-25 | 2018-09-04 | Onclave Therapeutics Limited | formulações de anticorpos e métodos |
| EP2798077A2 (en) | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
| WO2013123114A2 (en) * | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| CZ2012829A3 (cs) | 2012-11-23 | 2014-06-11 | Biotechnologický Ústav Av Čr, V.V.I. | Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EP3689369A1 (en) | 2013-03-15 | 2020-08-05 | Amgen, Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| US20160031983A1 (en) | 2013-03-15 | 2016-02-04 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| KR20170120616A (ko) | 2015-02-04 | 2017-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| MX2018003376A (es) | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| HK1255922A1 (zh) | 2015-11-04 | 2019-09-06 | Astrazeneca Ab | 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子 |
| WO2017112536A1 (en) | 2015-12-22 | 2017-06-29 | Amgen Inc. | Ccl20 as a predictor of clinical response to il23-antagonists |
| RU2732111C2 (ru) | 2016-01-22 | 2020-09-11 | Бакстер Интернэшнл Инк. | Мешок для стерильного раствора продукта |
| PH12022551159A1 (en) | 2016-01-22 | 2023-05-08 | Baxter Healthcare Sa | Method and machine for producing sterile solution product bags |
| MX2019007824A (es) | 2016-12-28 | 2019-09-09 | Japan Chem Res | Preparacion liofilizada. |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| JP2021532176A (ja) | 2018-07-13 | 2021-11-25 | アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニーAstrazeneca Collaboration Ventures, Llc | ブラジクマブによる潰瘍性大腸炎の処置 |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| US12098195B2 (en) | 2018-11-27 | 2024-09-24 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-IL-23p19 antibody and use thereof in treating diseases |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| MX2021012652A (es) * | 2019-04-15 | 2022-01-24 | Sun Pharmaceutical Ind Ltd | Metodos para el tratamiento de sujetos con artritis psoriasica. |
| TW202535466A (zh) * | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| GB202107153D0 (en) * | 2021-05-19 | 2021-06-30 | UCB Biopharma SRL | Method for filling vials containing liquid drug products |
| CN115785267B (zh) * | 2021-09-10 | 2023-12-15 | 三优生物医药(上海)有限公司 | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP1820516B1 (en) | 1999-02-22 | 2013-07-24 | University of Connecticut | Novel albumin-free factor VIII formulations |
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| CN103040732B (zh) | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| KR20060080535A (ko) * | 2003-05-14 | 2006-07-10 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| WO2005035574A1 (ja) * | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | IgM高濃度安定化溶液 |
| BRPI0611800A2 (pt) | 2005-06-15 | 2008-12-09 | Schering Corp | formulaÇço estÁvel de anticorpo |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI1937721T1 (sl) | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| SI3219328T1 (sl) * | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| AU2007223903B2 (en) * | 2006-03-06 | 2013-09-05 | Medimmune, Llc | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| WO2008088823A2 (en) * | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
-
2009
- 2009-08-25 WO PCT/US2009/054842 patent/WO2010027766A1/en not_active Ceased
- 2009-08-25 AU AU2009288419A patent/AU2009288419B2/en active Active
- 2009-08-25 CN CN2009801428023A patent/CN102202655B/zh active Active
- 2009-08-25 US US13/061,076 patent/US8263748B2/en active Active
- 2009-08-25 EP EP09791868A patent/EP2331078B1/en active Active
- 2009-08-25 JP JP2011525134A patent/JP5931442B2/ja active Active
- 2009-08-25 CA CA2734919A patent/CA2734919C/en active Active
- 2009-08-25 MX MX2011002159A patent/MX2011002159A/es active IP Right Grant
-
2015
- 2015-09-17 JP JP2015184258A patent/JP2016028086A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7528249B2 (ja) | Ｃｏｖｉｄ－１９に対する抗原特異的免疫療法、融合タンパク質、およびその使用方法 | |
| Tai et al. | A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection | |
| Huleatt et al. | A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity | |
| Sun et al. | Thermal stability of self-assembled peptide vaccine materials | |
| US9861696B2 (en) | Monoclonal antibodies for Ebola and Marburg viruses | |
| JP5960120B2 (ja) | ウイルス粒子の安定化 | |
| US20230181730A1 (en) | Methods of treating infections | |
| BR112021004193A2 (pt) | vacinas pneumocócicas multivalentes | |
| JP2016534052A5 (enExample) | ||
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| Stinson et al. | Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine | |
| Nguyen et al. | The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents | |
| JP2006511448A5 (enExample) | ||
| US11406704B2 (en) | Adjuvants | |
| TWI615158B (zh) | 多肽之調配物 | |
| KR20130114210A (ko) | 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 | |
| KR102922338B1 (ko) | 폐렴구균 융합 단백질 백신 | |
| JPS58213723A (ja) | 口蹄疫ウイルス抗原の特異性を有する小型ペプチド | |
| Demircan et al. | Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response | |
| US20230210980A1 (en) | Chimeric adenoviral vectors | |
| KR20230135598A (ko) | 안정한 코로나바이러스 단백질 및 그의 백신 조성물 | |
| US20230233667A1 (en) | Coronavirus vaccine | |
| JP2022525431A (ja) | 抗原性多量体呼吸器合胞体ウイルスポリペプチド | |
| Mittal et al. | Enhanced protective efficacy of a novel, thermostable, RBD-S2 vaccine formulation against SARS-CoV-2 and its variants | |
| US10829542B2 (en) | Methods for affecting Salmonella infections |